Clinical Trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Location:
Trial status:
InactiveWhy is this study being done?
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.
Who is eligible to participate?
Inclusion Criteria:
- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
- Disease progression following non-steroidal aromatase inhibitor treatment
Exclusion Criteria:
- Known symptomatic brain metastasis
- Medical condition requiring chronic steroids
- History of Type 1 or 2 Diabetes
- Uncontrolled or significant cardiovascular (CV) disease
- Concomitant second malignancies
Last updated: 03/28/2013
NCT ID:
NCT01225172- Legal restrictions and terms of use applicable to this site
- Use of this site signifies your agreement to the terms of use.
- © 1998-2012 Mayo Foundation for Medical Education and Research. All rights reserved.